Dr. Reddy's Laboratories announces the launch of Penicillamine Capsules USP, 250 mg in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Penicillamine Capsules USP, 250 mg, a therapeutic equivalent generic version of Cuprimine® (penicillamine) Capsules, 250 mg, approved by the U.S. Food and Drug Administration (USFDA).

The Cuprimine® brand and generic market had U.S. sales of approximately $80 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health*.

Dr. Reddy's Penicillamine Capsules, USP is available as 250 mg capsules in a bottle count sizes of 100.

Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.4437.75 as compared to the previous close of Rs. 4425.4. The total number of shares traded during the day was 16491 in over 1665 trades.

The stock hit an intraday high of Rs. 4449.95 and intraday low of 4401. The net turnover during the day was Rs. 72892118.

Source : Equity Bulls

Keywords